Literature DB >> 27143022

Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?

Toshiaki Iba1, Jecko Thachil2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27143022     DOI： 10.1007/s00134-016-4288-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

2.  Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Authors:  J Kienast; M Juers; C J Wiedermann; J N Hoffmann; H Ostermann; R Strauss; H-O Keinecke; B L Warren; S M Opal
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

3.  Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.

Authors:  T Tagami; H Matsui; H Horiguchi; K Fushimi; H Yasunaga
Journal:  J Thromb Haemost       Date:  2014-07-16       Impact factor: 5.824

Review 4.  Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials.

Authors:  Y Umemura; K Yamakawa; H Ogura; H Yuhara; S Fujimi
Journal:  J Thromb Haemost       Date:  2016-02-01       Impact factor: 5.824

Review 5.  Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Mikkel Allingstrup; Jørn Wetterslev; Frederikke B Ravn; Ann Merete Møller; Arash Afshari
Journal:  Intensive Care Med       Date:  2016-02-09       Impact factor: 17.440
  5 in total
  2 in total

1.  Molecular basis of coronary artery dilation and aneurysms in patients with Kawasaki disease based on differential protein expression.

Authors:  Wanting Liu; Chaowu Liu; Li Zhang; Xiaofei Xie; Xiaoqiong Gu; Chuanlan Sang; Mingguo Xu; Weijun Xu; Hongling Jia
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

Review 2.  To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Semin Thromb Hemost       Date:  2017-08-04       Impact factor: 4.180
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.